Lyell Immunopharma (LYEL) Retained Earnings (2020 - 2026)
Lyell Immunopharma recorded quarterly Retained Earnings of -$9000.0 in Q1 2026, down 103.72% quarter-over-quarter from $242000.0 in Q4 2025, and up 100.0% year-over-year from -$4500.0 in Q1 2025.
Lyell Immunopharma's Retained Earnings history runs 7 years deep, the most recent figure standing at -$9000.0 for Q1 2026.
- In Q1 2026, Retained Earnings rose 100.0% year-over-year to -$9000.0; the TTM figure through Mar 2026 stood at -$9000.0 (up 100.0% YoY), while the FY2025 annual figure was $242000.0, down 16.84% from the prior year.
- Retained Earnings came in at -$9000.0 for Q1 2026 at Lyell Immunopharma, down from $242000.0 in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $760000.0 in Q3 2024 to a low of -$1.4 billion in Q2 2025.
- A 5-year average of -$446.5 million and a median of -$8.4 million in 2022 frame the typical range for Retained Earnings.
- On a YoY basis, Retained Earnings climbed as much as 164.35% in 2024 and fell as far as 27298.27% in 2024.
- Lyell Immunopharma's Retained Earnings stood at -$7.6 million in 2022, then plunged by 13087.42% to -$1.0 billion in 2023, then soared by 100.03% to $291000.0 in 2024, then declined by 16.84% to $242000.0 in 2025, then plunged by 103.72% to -$9000.0 in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered -$9000.0, $242000.0, and $201000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 130.89 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 36.42 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | -24.89 Mn |
| 10 | Lyell Immunopharma | 379.11 Mn | 379.11 Mn | - | -9,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -9,000.00 |
| Dec 31, 2025 | 242,000.00 |
| Sep 30, 2025 | 201,000.00 |
| Jun 30, 2025 | -1.44 Bn |
| Mar 31, 2025 | -1.40 Bn |
| Dec 31, 2024 | 291,000.00 |
| Sep 30, 2024 | 760,000.00 |
| Jun 30, 2024 | -1.11 Bn |
| Mar 31, 2024 | -1.06 Bn |
| Dec 31, 2023 | -1.00 Bn |
| Sep 30, 2023 | -1.18 Mn |
| Jun 30, 2023 | -898.33 Mn |
| Mar 31, 2023 | -3.88 Mn |
| Dec 31, 2022 | -7.60 Mn |
| Sep 30, 2022 | -10.00 Mn |
| Jun 30, 2022 | -8.35 Mn |
| Mar 31, 2022 | -652.51 Mn |
| Dec 31, 2021 | -1.62 Mn |
| Sep 30, 2021 | -65,000.00 |
| Jun 30, 2021 | -451.78 Mn |
| Dec 31, 2020 | 256,000.00 |